Skip to content
DataLookout
Menu

NCT06952478

A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 3
SponsorCelltrion
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 6 more changesShow less
    • Eligibility criteria expanded, about 20 words
    • Enrollment closed, study ongoing
    • Primary completion moved earlier from Nov 15, 2027 to Mar 8, 2027
    • Study completion moved earlier from Jun 25, 2029 to Sep 18, 2028
    • Enrollment target: estimated 486 to confirmed 473
    • Site details revised
  2. Minor Start date changed from estimate of Jul 20, 2025 to Aug 12, 2025v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 31, 2025 to Jul 20, 2025
    • Study sites: 0 to 1
    v3
  4. Notable Eligibility criteria shortened, about 15 words
    • Study title shortened, about 2 words
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

PK equivalence of CT-P44 and Darzalex Faspro
Timeframe: Week 0 ~ Week 24

Arms and interventions

CT-P44Experimental

CT-P44 1800mg SC (subcutaneous)

Darzalex FasproActive comparator

Darzalex Faspro 1800mg SC (subcutaneous)

Biologicals: CT-P44(Daratumumab), Darzalex Faspro(Daratumumab)

Sites

1 site in 1 country

  • Taipei Veterans General HospitalTaipei, Beitou District, Taiwan